Analyse Pyxis Oncology, Inc. (PYXS) — Kairos Score 55/100

À propos de Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

1 transactions — 1 achats et 0 ventes déclarés par les dirigeants de Pyxis Oncology, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur PYXS dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur PYXS.

• Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
• Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.